New York-based Neurogene raised $68.5 million in a Series A funding round to support the company’s pipeline of therapeutics aimed at rare neurological diseases.

Durham, North Carolina-based Ribometrix closed on a Series A financing worth $30 million, led by M Ventures.

Backed by GlaxoSmithKline and Boston’s SV Health Investors, a new biopharmaceutical company known as Sitryx launched with $30 million in a Series A funding round.

Boston-based biotech company Karuna Pharmaceuticals completed a $42 million Series A financing. The round included the issuance of $22 million in shares upon conversion of debt into equity.

Tmunity Therapeutics closed on a Series A financing worth $100 million. Syndicate investors included Ping An Ventures, Parker Institute for Cancer Immunotherapy, Gilead Sciences, and Be The Match BioTherapies.

BioSpace present its NextGen Bio “Class of 2018,” a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.

Jnana Therapeutics launched with a $50 million Series A financing. Seed funders Polaris Partners and Avalon Ventures were joined in the round by Versant Ventures, AbbVie Ventures and Pfizer R&D Innovate.

The health marketing and commercialization agency continues focus on growing healthcare commercialization practice and introducing more innovative business models to industry.

The Biotechnology Industry Organization released a report titled: Emerging Therapeutic Company Investment and Deal Trends. BIO Industry Analysis says more than 90 percent of the biopharma industry is composed of small, emerging companies. According to BIO President Jim Greenwood and E. Cartier Esham, Ph.D., executive VP of BIO’s Emerging Companies Section, it is important for the trade association to better understand early-stage investor and deal-making trends in order to determine where scientific or policy issues may be affecting the ability to maintain a robust pipeline of innovative medicines.

Startup Homology Medicines Launches With $43 Million Series A, To Be Led By Three Former Shire Execs   May 2, 2016By Mark Terry, BioSpace.com Breaking News Staff   Lexington, Mass.-based Homology Medicines launched today with a $43.5 million Series A preferred stock financing. The round was co-led by 5AM Ventures and ARCH Venture Partners. They […]